AstraZeneca PLC's PD-L1 inhibitor, Imfinzi (durvalumab), a drug expected to act as the big pharma's backbone drug across its cancer immunotherapy portfolio, has failed to meet primary progression free survival (PFS) endpoints in the Phase III MYSTIC trial in non-small cell lung cancer.
In the Phase III study Imfinzi, a program death-ligand 1 inhibitor, in combination with tremelimumab failed to improve PFS compared to platinum-based standard of care chemotherapy in previously-untreated patients with
2Q Numbers At A Glance
- Total revenue: $5.1bn
- Core EPS: $0.87
- Tagrisso sales: $232m
- Imfinzi sales (launched in May 2017): $1m
- Oncology sales: $993m
- Respiratory sales: $1.1bn
- Cardiovascular and metabolic sales: $1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?